Business Wire

Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

The drug is under Priority Review by the U.S. Food and Drug Administration (FDA) and has a Prescription Drug User Fee Act (PDUFA) date of June 23, 2025 NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc.
Business Wire

Delve Bio Presents Data Showing Metagenomic Next-Generation Sequencing (mNGS) Delivers Greater Diagnostic Yield Than Conventional Methods in Central Nervous System Infections

In the largest study of its kind, the diagnostic yield of mNGS was greater than conventional test methods mNGS alone identified 34% more pathogens than all direct-detection methods combined 72% of ...
Nasdaq

Passage Bio Reports Promising Interim Data for PBFT02 in FTD-GRN Patients and Provides Business Updates

Passage Bio, Inc. announced interim results from its PBFT02 clinical trial for frontotemporal dementia (FTD) patients with the GRN mutation, revealing significant increases in cerebrospinal fluid (CSF ...
Seeking Alpha

Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success

Instil Bio (TIL) and its partner ImmuneOnco have been doing well to advance their potential best-in-class PD-1/VEGF bispecific antibody AXN-2510 for the treatment of patients with solid tumors. The ...
Seeking Alpha

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition

The last time I spoke about Tourmaline Bio (TRML) it was with respect to a Seeking Alpha article entitled "Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting." In this article, I ...